DLI is an effective strategy for patients with recurrent hematological malignancies after allogeneic hematopoietic SCT (allo-HSCT). DLI has been widely applied to boost the graft vs tumor (GVT) or GVL effects. However, given the potentially severe complications associated with conventional DLI and transient GVL effect, new strategies for DLI are emerging. In this review, we have discussed the recent important studies on DLI as a prophylactic or therapeutic modality for relapsed hematological disorders after allo-HSCT. The strategies to separate GVL from GVHD have also been discussed. Leukemia-targeting therapy and lymphodepletion combined with DLI, and prophylactic DLI after allo-HSCT are often employed for patients with high risk of relapse, which has been reviewed as well. In addition, we have also discussed the issues on DLI to be further addressed, such as the doses, timing and frequency of DLI in different clinical settings, leukemic antigen-specific DLI as well as how to augment GVL effect while attenuating GVHD.
INTRODUCTION
Over the last few decades, allo-HSCT has become the significant treatment choice for refractory and relapsed hematological malignancies to provide long-term survival and even cure. [1] [2] [3] However, relapse after transplantation remains a major cause of treatment failure. [3] [4] [5] [6] To improve the effect of allo-HSCT, a variety of strategies has been explored. A growing body of evidence has shown that DLI is currently an effective therapeutic approach for patients with recurrent hematological malignancies after allo-HSCT. As a prophylactic or therapeutic regimen, DLI has been widely employed to boost the graft-vs-tumor (GVT) or GVL effects. 3, 6, 7 Clinical data have shown that DLI is most effective for CML [7] [8] [9] [10] and the response rate is 70-80% for hematological or cytogenetic relapse, 9 whereas the benefit of DLI for relapsed acute leukemia is often limited, 11 mainly because of the rapid growth of leukemic cell burden, poor response to the GVL reaction 9 and the development of GVHD 12 and aplasia. 8 To overcome these limitations, researchers have attempted to modify the DLI strategies depending on different clinical settings. In this review we have discussed the recent advances of these strategies, the clinical outcomes of DLI post allo-HSCT as well as the issues need to be further addressed.
MODIFIED THERAPEUTIC DLI
DLI is usually used to treat relapsed hematological malignancies after allo-HSCT in clinic. 10, 13 The potential GVL or GVT effects of DLI make it one of the favored treatment choices for recurrent diseases. 14, 15 Since Kolb et al. first reported sustained remission after DLI in patients with CML relapse after allogeneic BMT in 1990, 16 unmanipulated DLI has become the mainstay allogeneic cellular therapy. However, owing to high risk of GVHD, 17, 18 broad use of this monotherapy had been limited until 1996 when an Israeli group described a new approach using lymphocytes treated in vivo or in vitro with recombinant IL-2, by which better therapeutic response was achieved even in those who were previously resistant to unmanipulated DLI. 19 The aim of using DLI in hematological malignancies is to enhance the responsiveness and, at the same time, to lessen the toxicity. To this end, various strategies have been taken to modify DLI. Table 1 summarizes responsiveness and toxicity of recent modified DLI in patients who underwent allo-transplantation. Some of the strategies will be discussed herein.
Pharmaceutical agents combined with DLI It has been shown that DLI has an antileukemic effect; however, the effect of this treatment usually lasts for only 3-4 months because of reduced potency of infused lymphocytes and/or growing burden of leukemic cells. 20 To improve the prognosis, a strategy combining DLI with the leukemia-targeting therapy (that is, pharmacological agents) can be exploited. Pharmacological agents such as 5-azacytidine and imatinib have been associated with remissions when used with DLI in patients with AML or Ph+ ALL. Lubbert et al. 21 reported a clinical study testing 5-azacytidine therapy followed by DLI in relapsed AML or CMML patients after allo-HSCT. Patients received 5-azacitidine 100 mg daily subcutaneously on days 1-3 followed by DLI on day 10, and the next treatment cycle started after 3 weeks. The median number of cycles was 2 (range 1-10). A prolonged survival was observed in patients with o 1% blasts among peripheral blood 1 + cells/kg) after every two azacitidine cycles. Overall response rate was 30%, and five of them remained in CR for a median survival of 777 days. Better response was achieved in the patients with MDS and AML with MDS-related features (P = 0.01). Sixteen patients experienced GVHD (acute: 37%, chronic: 17%). In designing such studies, the following aspects have been emphasized: (a) the therapy should have immunomodulatory rather than immunosuppressive effects; (b) the regimen should have a low hematologic toxicity; (c) the treatment should have a documented antileukemic effect. As described above, epigenetic targeting agents such as azacitidine combined with DLI can elicit antileukemic effects but a relatively low hematological toxicity. 20, 23 Lymphodepletion followed by DLI Recently, lymphodepleting (LD) chemotherapy with fludarabine (Flu) and/or CY before the injection of donor lymphocytes has been used to modify the immune environment for enhancing the effectiveness of DLI, which is suggested to be associated with the suppression of regulatory T cells (Treg cells) during the LD process. [24] [25] [26] Miller et al. 27 pioneered the LD approach in the context of DLI after allo-HSCT. The dosage of CY was 50 mg/kg once on day − 6 accompanied with Flu 25 mg/m 2 for five consecutive days (−6 to − 2) and then donor lymphocyte was infused in a fixed high dose of 1 × 10 8 CD3 + cells/kg, given 48 h after the last Flu dose. They observed a significantly higher incidence of severe acute GVHD (cumulative acute II-IV: 60%) in comparison with DLI alone.
To minimize the risk of severe GVHD, Guillaume et al. 28 used a modified LD-DLI protocol to treat 18 patients with various non-CML hematological malignancies who relapsed following allo-HSCT. In this study, CY and Flu were given at the doses of 600 mg/m 2 on day 1 and 25 mg/m 2 /day on days 1-3, respectively. The results showed that cumulative incidence of acute grade II-IV GVHD was 29.4% and the 2-year OS was 39%. However, the expected significant decrease in Treg cells was not observed. The relatively small number of samples collected and/or the timing of analysis might account for the failure to detect the decrease in Tregs.
Another clinical study 25 from Paris evaluated the effect of LD chemotherapy combined with Treg-depleted DLI. A total of 17 adult patients with malignancy relapse after allo-HSCT were studied, and two of them developed GVHD after their first Treg-depleted DLI (2 × 10 7 CD3 + cells/kg) and experienced a longterm remission. Four of the fifteen patients who did not respond to the first Treg-depleted DLI received a second Treg-depleted DLI combined with LD chemotherapy (CY 1 g/m 2 on day − 5 and Flu 30 mg/m 2 /day on days − 5 to − 2 before infusion) also aiming at eliminating recipient Tregs. All four patients developed acute-like GVHD that was associated with a partial or complete and durable remission. GVHD induction through Treg depletion may improve survival. These results suggest that the combined chemotherapyinduced LD synergizes with Treg-depleted DLI in improving GVL effect. However, the worsened GVHD is a potential risk. Thus, when considering this strategy, the pros and cons must be all taken into account.
Activated DLI against relapse of primary hematologic malignancies after transplant Ex vivo donor T cells activated by anti-CD3-and anti-CD28-coated beads have been used as a form of activated DLI (aDLI). 29, 30 Porter and his colleagues treated 18 patients who relapsed after allo-HSCT with induction chemotherapy, and all patients received unmanipulated DLI (median, 1.5 × 10 8 mononuclear cells/kg) followed 12 days later by aDLI (escalated CD3+ T cell dose from 1 × 10 6 -1 × 10 8 /kg in five levels). T cells were expanded ex vivo via CD3/CD28 stimulation in this study. Seven patients developed aGVHD and four developed cGVHD. Eight patients including AML, ALL, CLL and NHL achieved CR. Ten patients were alive after 11-53 months. This study demonstrates that aDLI has potent GVL effect without causing excessive toxicity and may lead to durable remissions in diseases especially where unmanipulated DLI has been disappointing.
30
CD4+ T-cell-enriched DLI T-cell exhaustion has been increasingly recognized as an important immunoevasive strategy in both solid and hematologic malignancies. [31] [32] [33] [34] Hence, it is a key in mediating an effective antileukemia response by the reverse of T-cell exhaustion for DLI. There is evidence that CD8-depleted (CD4+) DLI can lead to a rapid expansion of pre-existing marrow-resident leukemia-specific CD8+ T cells, followed by a cascade of peripheral B-and T-antigenspecific immune responses. 35 These infiltrating T cells in the site of disease are very critical to tumor control. 36, 37 Bachireddy et al. /kg CD4+ T cells as DLI. OS and PFS at 2 years after DLI were 93% and 92%, respectively. Twenty-two patients were detected with the disappearance of marrow BCR-ABL+ cells. In these DLI responders, the significantly increased levels of CD8+ T cells were detected at 3-6 months, which persisted at similar levels to 9-12 months post DLI. This study supports the idea that CD4+ DLI provides immunologic help for marrow-residing, likely exhausted tumor-specific CD8+ T cells to awaken antitumor immunity. In another study at the University of Hamburg, 18 CD4+-selected DLI was used to treat 24 patients after transplantation. During a median follow-up of 25 months, seven patients experienced GVHD (acute II-IV: 17%, acute III-IV: 8%, chronic GVHD (cGVHD): 12%). Thirteen of twenty-one (62%) patients who underwent further evaluation showed measurable clinical response, and overall 2-year survival for all patients was 91%. Despite CD4+ T-cell-enriched DLI shows its promise against tumor relapse post-allogeneic HSCT in the above small cohort studies, larger double-blind randomized multicenter studies are needed to further establish the efficacy of CD4+ T-cellselected DLI.
Growth factor-primed DLI G-CSF-mobilized donor lymphocytes are widely applied as a method of modified DLI. [39] [40] [41] Levine et al. employed a salvage strategy with chemotherapy, followed by G-CSF-primed DLI for relapsed patients after BMT. Twenty-seven of fifty-seven assessable patients experienced a CR. In spite of GVHD occurrence of 56%, treatment-related mortality of 23% and OS of 19% at 2 years for the entire cohort, 1-and 2-year survival rates of patients with a CR were 51% and 41%, respectively. This approach can help certain patients with advanced myeloid relapse after BMT. 42 Choi et al. 40 tested the efficacy of chemotherapy followed by G-CSF-primed DLI in 16 relapsed AML patients after allogeneic BMT. Ten of them achieved CR and the 2-year OS was 31%, which suggests that chemo-DLI can induce high remission rate in relapsed AML patients previously receiving allo-HSCT. Thus, G-CSF-primed DLI could be a potential approach to treat relapsed leukemia post HSCT; however, in a recent clinical study, G-CSF-primed DLI was not shown to be superior to conventional DLI. 43 Consistent with this study, Curley et al. 44 performed a retrospective analysis of 32 relapsed acute leukemia patients after allo-HSCT. Nineteen of them received Flu, Cytarabine and G-CSF (FLAG) induction chemotherapy followed by G-CSF-mobilized DLI and the rest of 13 patients received the same stepwise therapy but no DLI. With a median follow-up of 47 months, the median OS and the occurrence of acute GVHD were not statistically different. Thus, G-CSF-primed DLI may behave differently depending upon the clinical conditions, and the evidence has shown that it may have a better role in the case of mixed chimerism, molecular or cytogenetic relapse and prophylactic therapy. [39] [40] [41] The rapid pace of the relapsed disease sometimes largely impedes the effect of DLI against acute leukemia. In addition, insufficient antigen presentation by the leukemic blasts with reduced or missing expression of co-stimulatory molecules to fail to induce significant T-cell proliferation could be another reason for the inferior DLI results. 45 To solve these problems, Schmid et al. 45 combined three elements for recurrent acute myeloid leukemia after allo-HSCT including the use of low-dose cytosine arabinoside as the first-line chemotherapy, the transfusion of G-CSF-mobilized donor blood cells, and the use of GM-CSF after donor cell transfusion for further stimulation of allogeneic immunity. In this study, the CR rate of 67% was observed in the entire cohort, and 2-year OS was 29% in all patients and 45% in responders. TRM was 25%. A longer remission post transplant, better disease control by low-dose cytosine arabinoside and occurrence of cGVHD after mobilized donor blood cell were associated with better survival.
Huang's group exploited DLI with G-CSF-mobilized peripheral blood progenitor cells designated as mDLI for therapeutic or prophylactic infusion, followed by the use of short-term immunosuppressive agents for GVHD prophylaxis. They retrospectively compared the antileukemia effects of chemotherapy alone and chemo-mDLI in 82 patients with relapsed AL after haploidentical HSCT. The CR rate and DFS were significantly higher in chemomDLI group (64% vs 12.5%; 36% vs 0%), and the incidence of relapse was significantly lower in the chemo-mDLI group in contrast to the chemotherapy group. In addition, this study also demonstrated that the lack of cGVHD and the duration of minimal residual disease (MRD; − ) o 4 months after mDLI were associated with higher relapse rates in patients receiving chemo-mDLI. 46 In studying the impact of GVHD prophylaxis with immunosuppressive agents in leukemia patients after HLA-identical sibling HSCT, they observed a significant difference between the patients without GVHD prophylaxis or with GVHD prophylaxis for less than 2 weeks and those with GVHD prophylaxis for over 2 weeks (CYA or MTX at 10 mg/week) with regard to the incidence of DLI-associated acute GVHD (14/28 vs 3/42, P o 0.01). In 31 patients with therapeutic DLI, the 5-year OS was 90% in the group with GVHD prophylaxis for over 2 weeks compared with 22% in the group with no/shorter GVHD prophylaxis. 47 Moreover, further study from the same group showed that prophylaxis with immunosuppressive agents for 6-8 weeks after modified DLI significantly reduced the incidence of DLI-associated aGVHD, but did not reduce GVL effect and improved OS and DFS in comparison with prophylaxis for o 6 weeks. 48 Several studies have also confirmed that post-DLI immunosuppression can significantly attenuate GVHD, without compromising GVL effects. [47] [48] [49] [50] In studying immuosuppressive strategy post mDLI, Huang's group compared low-dose MTX with CYA on GVHD and GVL effects after haploidentical mDLI in relapsed acute leukemia patients undergoing HSCT. Despite the incidence of aGVHD and grade 2-4 aGVHD in the MTX group showed a trend toward being higher when compared with CSA-treated group (61% vs 37.3%, P = 0.198 and 61% vs 35.5%, P = 0.155), patients treated with MTX had lower re-relapse rate (38.1% vs 80.8%, P = 0.029), better DFS (51.9% vs 15.6%, P = 0.06) and higher absolute lymphocyte counts at 30, 45, 60 and 90 days after mDLI (Po 0.05). These results suggest that low-dose MTX administration post mDLI could lead to stronger GVL effect and less DLI-associated GVHD. 51 Given the risk of high-intensity conditioning regimen and high TRM of a second transplant often chosen for a certain group of patients with relapsed diseases, 15 ,40,52,53 modified DLI described above could be worthy alternative approaches for those patients. 47 These approaches most likely exert their effect via modulating immune responses. Although there is a possibility that G-CSF-mobilized hematopoietic stem cells (HSCs) engraft under immunosuppression and/or combined chemotherapy, the condition would not be sufficient for full engraftment of infused HSCs during mDLI. In addition, second HSCT requires a certain number of CD34+ HSCs in G-CSF-mobilized peripheral mononuclear cells, which may not be required for mDLI.
PREEMPTIVE AND PROPHYLACTIC DLI
Strategies to prevent relapse after transplant are highly desirable, especially in the case of T-cell depletion such as T-cell-depleted grafts and non-myeloablative HSCT. 54 Currently, preemptive and prophylactic DLI (pDLI) is widely used to minimize the risk of post-transplant relapse for patients receiving T-cell depletion 55 and having diseases at advanced stage. 55, 56 pDLI is also often administered for promoting FDC, enhancing immune reconstitution, 27, 57, 58 as well as treating virus infection after HSCT and preventing viral reactivation. 59 G-CSF-primed pDLI To explore the relationship between pDLI and risk stratificationdirected interventions for MRD, Yan et al. 60 executed a clinical study in which a total of 709 patients were divided into three groups (group A: MRD − after transplantation; group B: MRD + receiving low-dose IL-2; group C: MRD + receiving G-CSF-primed modified DLI with or without low-dose IL-2). Post-transplant immune suppression for GVHD was modified based on the MRD state. The results showed that lower cumulative risk of relapse and higher disease-free survival (DFS) were observed in group C than in group B, but were not different from patients in group A. This finding highlights the importance of DLI in improving transplantation prognosis through preventing the relapse of the primary diseases. 8 Similarly, a multicenter study conducted by Wang et al. 61 enrolled a total of 123 patients with advanced-stage acute leukemia receiving HSCT. Fifty of them received prophylactic G-CSF-primed DLI with a short-term GVHD prophylaxis and the incidence of acute grade II-IV GVHD was 17% compared with 23% for patients not receiving DLI. The reduced acute GVHD might be associated with immunoregulatory characteristics of G-CSFmobilized cells. 62 The 2-year cumulative incidence of relapse was significantly lower in the pDLI group (46%) than in the non-DLI group (66%), and the 3-year OS and leukemia-free survival were significantly higher in the pDLI group than in the non-DLI group. It is worth noting that in this study the incidence of cGVHD in the DLI group was 38% but only 17% in the non-DLI group. The authors explained that this higher incidence of cGVHD might be related to lower relapse rate and longer survival in the DLI group. In line with this study, other studies have also shown that the use of prophylactic infusion of G-CSF-mobilized PBPCs prolongs the survival of advanced-stage acute leukemia patients after allo-HSCT. 63, 64 Activated pDLI Porter et al. 30 previously reported that DLI using ex vivo expanded T cells stimulated by anti-CD3-and anti-CD28-coated beads was safe and had potent GVL effect. Recently, they demonstrated that the prophylactic aDLI could be given safely and was able to prevent relapse in high-risk patients after allo-HSCT. 64 However, the treatment may fail because of disease progression, and GVHD remains a major concern of using aDLI. Thus, alternative strategies of minimizing GVHD while maximizing GVL need to be further explored.
Other modified pDLIs Recently, Liga et al. 65 reported that, even though low-dose pDLI was employed, the high alloreactivity remained in patients with acute leukemia undergoing allo-HSCT with an alemtuzumabcontaining conditioning regimen. Owing to this, during the observation period, no relapse was reported but a high incidence of severe GVHD was observed. Fowler et al. performed a phase 2 multicenter clinical trial using rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after HLA-matched sibling donor all-HSCT for therapy of refractory hematologic malignancies. T-Rapa cell products, which expressed a balanced Th2/Th1 phenotype, were administered as a preemptive DLI on day 14 post HSCT. After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential immune reconstitution with donor CD4 + Th2 and Th1 cells relative to Treg cells and CD8 + T cells. The cumulative incidence probability of acute GVHD was 20% and 40% on days 100 and 180 post HCT, respectively. There was no TRM. Eighteen of fourty patients (45%) remain in sustained CR at 7-year follow-up. 66 To reduce the risk of relapse after HSCT, Horn et al. 67 prospectively studied post-transplant chimerismbased immunotherapyusing fast withdrawal of immunosuppression and DLI in children with early post-transplant mixed chimerism. Patients with mixed chimerism undergoing immunotherapy had similar 2-year EFS compared with patients who achieved full donor chimerism (FDC) spontaneously. There were no late relapses in the observation group. EFS in the entire cohort was 58% at 42 months after transplantation. This study suggests that DLI improves the clinical outcome likely through promoting FDC conversion.
GVHD AND GVL AFTER DLI
The main purpose of using DLI is to elicit a GVL effect. However, the potentially severe GVHD after DLI largely hampers the clinical application of DLI. GVHD is the most common and significant toxicity after DLI. 68 The cumulative incidence of acute GVHD is 40-60%. cGVHD occurs in 33-61% of patients, and the deaths attributable to GVHD are in the range of 6-11% when unmanipulated DLI is given for relapsed hematological malignancies after myeloablative related transplants. [69] [70] [71] [72] [73] Thus, it is highly desirable that the DLI protocol augments the GVL effect without leading to severe GVHD.
Incidence of GVHD and GVL post DLI Similar to allo-HSCT, one of the most important complications in DLI is GVHD. 3 It is unclear what factors determine the incidence and severity of DLI-induced GVHD. It is often assumed that unrelated donor HSCT might lead to GVHD with higher incidence and greater severity in contrast to related donor HSCT. However, the clinical data do not completely support this assumption. Studies have shown that when unrelated DLI was evaluated as an independent risk factor after unrelated allo-HSCT; no increased risk of GVHD was found. 74, 75 Similarly, several retrospective studies also suggested no significant difference between unrelated and related DLI in the incidence of GVHD. [76] [77] [78] Limited clinical data are available on haploidentical DLI. As haploidentical HSCT has been employed worldwide, 79 it is expected that a series of studies on haploidentical DLI will be available in the near future. Nevertheless, it has been shown that whether it is for prophylactic or therapeutic purpose, haploidentical DLI is associated with a high GVHD rate unless given in a very low dose (1 × 10 4 CD3+ T cells/kg). 80 This small dose is shown to be beneficial for immune reconstitution but its GVT activity is still inconclusive. Therefore, in order to enhance the GVL effect of haploidentical DLI with relatively large doses, combination with prophylactic immunosuppressive agents against GVHD should be considered. In addition, DLI after non-myeloablative HSCT is being used frequently to convert a mixed chimerism to a full chimerism in an effort to prevent relapse and limit toxicity. Data from murine models have shown that the chimerism conversion did not increase GVHD. 70, 81 However, some clinical studies suggested that only one-third of evaluable patients were converted from mixed to FDC on DLI administration after HLA-matched nonmyeloablative BMT, and patients with donor T-cell chimerism below 50% rarely responded. 82, 83 Durakovic et al. 84 demonstrated that in vivo administration of Toll-like receptor (TLR) ligands was able to maximize DLI-mediated lymphohematopoietic graft-vs-host and GVL reactivity in chimeras with low levels (⩽15%) of residual host chimerism. In this study, it was also shown that, in the absence of tissue damage, TLR ligands could augment the GVL effect of MHC-matched DLI mediated by anti-mHAg responses without inducing lethal GVHD, which is highly associated with conversion to complete donor T-cell chimerism after HLA-matched nonmyeloablative allografting.
Separation of GVL from GVHD Notably, the disease response to conventional DLI and the presence of GVHD are highly correlated. [85] [86] [87] Therefore, it is very important to separate GVL from GVHD. Much current effort is focused on enhancing the GVL effect, or preventing GVHD without impairing the GVL effect through identification and utilization of optimal donors, dose-escalation schemes, CD8+ T-cell depletion 88 and tumor-specific DLI.
To reduce the risk of GVHD, patients and donors are preferably matched for HLA-A, -B, -C, -DRB1 and -DQB1 (refs 89,90) . HLA-DPB1 is often not taken into consideration in donor selection because it has no significant effect on overall mortality of patients in allotransplant; 54 however, HLA-DPB1-mismatched allo-HSCT is associated with a decreased risk of disease relapse and an increased risk of GVHD compared with HLA-DPB1-matched allo-HSCT. [91] [92] [93] [94] As described in some studies, 19, 92 in T-cell-depleted allo-HSCT, mismatching for HLA-DPB1 was not associated with an increased risk of GVHD, but highly correlated with a significantly decreased risk of disease relapse. To further explore the responses of HLA-DP-specific CD4+T cells in patients undergoing T-cell-depleted HLA-DPB1-mismatched allo-HSCT and DLI, Caroline et al. analyzed 24 patient-donor combinations and screened for the presence of HLA-DP-specific CD4+T cells using CD137 as an activation marker. The results showed that patient HLA-DP-specific CD4+T cells were detected after DLI in 13 of 18 patients who exhibited a clinical response to DLI, which is much higher than 1 of 6 patients who failed to achieve a clinical response to DLI. Eight patients developed significant GVHD. These data illustrate an association between the presence of patient HLA-DP-specific CD4+T cells and the development of both the clinical responses and GVHD. 19 The expression of herpes simplex thymidine kinase suicide gene was confirmed to promote immune reconstitution and GVT effect, and reduce risk of GVHD in DLI. 95 Moreover, ganciclovir can be given to abort GVHD when necessary. Ciceri et al. 96 performed a multicenter non-randomized phase I-II study that 28 patients undergoing haploidentical SCTs received donor lymphocytes expressing herpes simplex thymidine kinase suicide gene (TK cells) starting 28 days after transplantation. The primary study end point was immune reconstitution defined as circulating CD3+ cell count up to 100/μl or more. The results showed that 22 patients obtained immune reconstitution at the median 75 days (range 34-127) from transplantation and 23 days from infusion. Ten patients who developed acute GVHD and one who developed cGVHD were controlled by induction of the suicide gene. OS at 3 years was 49% for 19 patients who were in remission from primary leukemia at the time of SCT. Another recent phase-I study from Japan evaluated the feasibility, safety and efficacy of TK cell infusion for the treatment of relapsed hematologic malignancies after allo-HSCT. Two of three patients achieved stable disease. There was no local or systemic toxicity related to infusion, and no severe GVHD requiring systemic steroid and/or ganciclovir administration. 95 These results suggest that infusion of TK cells might be beneficial to facilitate immune reconstitution, augmenting GVL effect, with GVHD and its associated mortality being controllable.
There is no doubt that one of the most exciting areas in current transplant research is the development of tumor-specific immune therapy. DLI with tumor-specific donor lymphocytes may be proven as one of the most effective approaches to separate GVT from GVHD. 97, 98 The clinical observations that some patients experience GVT without GVHD as well as the possibility of preparing leukemia-specific lymphocytes suggest that such approaches to treatment is possible. However, the major limitation to tumor-specific DLI would be the difficulties in identifying and isolating tumor-specific target antigens. 70, 86 CELL COMPOSITION OF DLI CD3+ T-cell dose At present, no available data demonstrate an optimal CD3+ T-cell dose for DLI probably because of multiple influencing factors such as the diversity of patients, the severity and diversity of diseases, the distinct DLI protocols used in different studies and the probability of GVHD to occur in the patients. The T-cell dose used in various studies ranges from 10 4 to 10 8 T cells/kg. [98] [99] [100] Abhinav et al. 101 reviewed the relationship of cell doses used for DLI and response rates in hematological malignancies. The data showed that a cell dose of less than 1 × 10 8 T cells/kg was suboptimal in CML but a cell dose of above 4.5 × 10 8 T cells/kg might lead to more complications, thereby potentially worsening the overall clinical results. In AML, the cell dose beyond 1.5 × 10 8 T cells/kg failed to increase the response rate. When evaluating the data from ALL, higher response rates were observed in studies using 1-2 × 10 8 T cells/kg. Of interest, the higher cell dose was associated with lower clinical response rates, for which the reason is not clear, may be that higher T-cell dose contains higher numbers of Treg cells, or the probable higher incidence of GVHD affects the overall clinical results. A comprehensive study conducted by Merav and co-workers evaluated the effect of initial DLI CD3+ cell dose on GVHD and OS after DLI against relapse of hematological malignancies post allo-HSCT. A total of 225 patients were divided into ⩽ 1 × 10 7 CD3+ cells/kg (n = 84; group A), 41.0 to o10 × 10 7 CD3+ cells/kg (n = 58; group B) and ⩾ 10 × 10 7 CD3+ cells/kg (n = 66; group C). Cumulative incidence rates of GVHD at 12 months after DLI were 21%, 45% and 55% for groups A, B and C, respectively. An initial DLI CD3+ cell dose of 10 × 10 7 or higher failed to decrease the risk of relapse and the OS was not improved. 102 Given that high dose does not lead to better clinical outcome but increases the incidence of GVHD, 76 DLI with high number of CD3+ T cells is not recommended in the clinical settings similar to that described above unless other measures to alleviate GVHD are taken. 103 However, discrepancies exist among different studies. Chalendon et al. 9 showed that GVHD was more frequent in patients with a higher cell dose for 410 7 CD3+ cells/kg than for o10 7 CD3+ cells/kg (47% vs 34%, Po 0.01) after DLI in patients with relapsed CML after allo-HSCT. Similarly, another study also showed that the dose of DLI (⩾1 × 10 7 ) was a predictive factor of acute GVHD. 7 In contrast to the studies described above, an earlier study by Choi et al. showed a better response rate with higher dose of T cells. 30 Notably, the patients in this study received chemotherapy of cytoreduction before DLI. Pretreatment by chemotherapy might, to a certain degree, contribute to the better clinical outcome.
Other cell compositions Many factors can influence the outcomes of patients who receive DLI after allo-HSCT. However, the exact role of DLI cell composition in these outcomes is unclear. To evaluate the impact of the cellular components of a modified DLI on the prognoses of patients, Huang and co-workers investigated the dose of infused CD3+, CD4+, CD8+, CD14+ and CD34+ cells. The results showed that infusion of a lower dose of CD14+ cells ( o0.33 × 10 8 /kg) was an independent risk factor for the occurrence of II-IV aGVHD (P = 0.032) in HLA-identical transplant patients. Specifically, the infusion of a greater number of CD14+ cells was associated with a lower incidence of hematological relapse and longer DFS (relapse: P = 0.007; DFS: P = 0.016). In contrast to this finding, a greater number of CD14+ cells was shown to be an independent risk factor for II-IV aGVHD (P = 0.034) in haploidentical allo-HSCT. These findings suggest that the cellular components of the modified DLI may have a distinct role in different types of allo-HSCT. Meanwhile, this study points a new direction for the development of cellular therapies by manipulating the components of infused cells. 104 
CONCLUSIONS
DLI is an important therapeutic option for preventing or treating the relapse of hematologic malignancies after allo-HSCT. It has also been used in other clinical settings such as advanced-stage diseases, inducing FDC and enhancing immune reconstitution. However, as a major obstacle, GVHD largely hampers the wide use of DLI in clinic. Therefore, a good approach would be to maximize GVL effect and in the meantime to minimize GVHD. The current available data on DLI studies will definitely provide very helpful information in guiding the development of future DLI protocols for different clinical settings. Tumor-specific targeting DLI is an attractive approach for it largely avoids GVHD while exerting stronger GVL effect. The protocols for prophylactic and therapeutic DLIs may require different modifications. The dose of infused cells, the timing and frequency of administration of DLI, and the maintenance of treatment need to be optimized for any given clinical setting. DLI combined with other immunemodulating agents such as anti-CTLA4 and anti-PD-1 for immunosuppressive factors can also be tested in the future. For this purpose, basic research as well as randomized double-blinded multicenter clinical trials will be needed in the future. Given that cancer immunotherapy has been selected as one of the 10 breakthroughs of 2013 in science by the Science journal and is positioned on top of this list, 105 future DLI studies will definitely benefit from what has been gained in cancer immunotherapy in other fields.
